Compare ZUMZ & SLGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ZUMZ | SLGL |
|---|---|---|
| Founded | 1978 | 1997 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Clothing/Shoe/Accessory Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 307.1M | 276.9M |
| IPO Year | 2005 | 2016 |
| Metric | ZUMZ | SLGL |
|---|---|---|
| Price | $18.18 | $80.00 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $18.00 | ★ $110.00 |
| AVG Volume (30 Days) | ★ 229.8K | 41.1K |
| Earning Date | 06-04-2026 | 05-22-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 966.67 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $929,057,000.00 | N/A |
| Revenue This Year | $4.30 | N/A |
| Revenue Next Year | $3.30 | $223.84 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 4.48 | N/A |
| 52 Week Low | $15.00 | $20.06 |
| 52 Week High | $31.70 | $97.97 |
| Indicator | ZUMZ | SLGL |
|---|---|---|
| Relative Strength Index (RSI) | 44.14 | 48.57 |
| Support Level | $17.00 | $67.89 |
| Resistance Level | $19.16 | $81.18 |
| Average True Range (ATR) | 0.64 | 6.41 |
| MACD | -0.18 | -0.77 |
| Stochastic Oscillator | 28.74 | 44.24 |
Zumiez Inc is a United States-based specialty retailer engaged in the sale of apparel, footwear, accessories, and hard goods. The company provides merchandise with cultural elements coming from fashion, music, art, action sports, streetwear, and other lifestyles. The company operates under the brands Zumiez, Fast Times, and Blue Tomato, and through both physical stores and websites. The majority of the company's stores are located in the U.S., with the rest in Canada, Australia, and Europe. The U.S. market contributes to the majority of the company's revenue.
Sol-Gel Technologies Ltd is a dermatology company. It is engaged in identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The company's product candidate pipeline includes SGT-610 (Patidegib Gel 2%), a new chemical entity hedgehog signaling pathway blocker, for the chronic use and prevention of new BCC in Gorlin syndrome patients, and the topical drug candidate SGT-210 for the treatment of Darier Disease and other rare keratosis-related indications such as PC, PPK and Olmsted. It generates the majority of its revenue from the United States.